Rubius Prepares Off-The-Shelf Red Cell Therapies For First Human Trial In 2018

Emerging Company Profile: Rubius Therapeutics is developing genetically engineered red blood cells and has raised $145m to take its first off-the-shelf, long-acting Red Cell Therapeutic into the clinic in 2018.

Emerging Company Profile Regular column feature image Version 2

Rubius Therapeutics Inc. is creating a new class of ready-to-use cellular therapies, which it hopes will have broader applicability than autologous chimeric antigen receptor T-cell (CAR-T) therapies and less frequent administration than traditional biologic medicines, with fewer side effects.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Start-Ups & SMEs

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By 

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.